Sign in

You're signed outSign in or to get full access.

Edsur Dara

Vice President and Equity Research Analyst at Barclays

Edsur Dara is a Vice President and Equity Research Analyst at Barclays specializing in biotechnology, with active coverage of companies such as Scholar Rock. Known for detailed corporate earnings analysis, Dara is recognized across key industry events and has delivered performance insights highly regarded by institutional clients. Dara began his career in equity research after completing postgraduate studies and joined Barclays as an analyst, where he continues to focus on innovative life sciences firms. He holds Series 7 and Series 63 securities licenses and is noted for professional rigor in biotechnology research.

Edsur Dara's questions to Scholar Rock Holding (SRRK) leadership

Question · Q3 2025

Edsur Dara asked what insights the FDA meeting minutes might provide regarding the type of BLA resubmission required and the potential review timelines once the BLA is refiled.

Answer

Akshay Vaishnaw, President of R&D, explained that the minutes are expected to reconfirm the impressions of Novo's progress and the agency's commitment. However, he noted that the FDA's practice is not to spell out review timelines for resubmissions in the minutes, but rather to await the BLA filing before determining those specifics. He reiterated the agency's supportive and urgent tone.

Ask follow-up questions

Fintool

Fintool can predict Scholar Rock Holding logo SRRK's earnings beat/miss a week before the call

Question · Q3 2025

Edsur Dara asked what insights the FDA's Type A meeting minutes might provide regarding the specific type of BLA resubmission required and the potential review timelines once the BLA is refiled.

Answer

CEO David Hallal and President of R&D Akshay Vaishnaw explained that while they await the official minutes to confirm impressions, the minutes typically do not detail review timelines for resubmissions. Akshay Vaishnaw reiterated that the meeting's tone was constructive, with shared support from all parties, including the agency, to expedite drug access for patients.

Ask follow-up questions

Fintool

Fintool can write a report on Scholar Rock Holding logo SRRK's next earnings in your company's style and formatting